Developer docs
API playgroundTry for free, no card

Search company profiles

APONTIS PHARMA

Full company profile

uuid0006om3

Namestring
APONTIS PHARMA
Legal namestring
APONTIS PHARMA Deutschland GmbH & Co. KG
Company typeenum
Public
Founded yearint
1946
Descriptiontext

APONTIS PHARMA Deutschland GmbH & Co. KG is a Germany-focused specialty pharmaceutical company headquartered in Monheim am Rhein, operating as 'The Single Pill Company'. It develops, in-licenses, and markets fixed-dose combination products ('Single Pills') that merge two to three off-patent active ingredients into a single tablet, primarily for cardiovascular indications including hypertension, dyslipidemia, and cardiovascular secondary prophylaxis. The portfolio currently includes 11 launched Single Pill brands (e.g., Tonotec, Caramlo, AmloAtor APONTIS, Iltria, RosuAmlo APONTIS) with a stated goal of at least 20 by 2026, alongside co-promoted respiratory products (Atectura Breezhaler, Enerzair Breezhaler) and legacy brands such as Colxi, magno sanol, and Obstinol M. The company was founded in 1946 as Schwarz Pharma, became part of UCB's Internal Medicine segment, was carved out in 2016, acquired by Paragon Partners in 2018, renamed APONTIS PHARMA in 2019, and completed an IPO in May 2021; it now operates as part of the Zentiva Group (Prague-headquartered) under joint GDPR controllership.

The company makes money primarily through wholesale pharmaceutical product sales in Germany, distributed through the regulated German pharma supply chain (wholesalers → pharmacies → patients, plus direct clinic supply under §14 Apothekengesetz). A secondary revenue stream comes from co-promotion and fee-for-call arrangements where APONTIS PHARMA deploys its field sales force to promote partner products to its established physician base. Go-to-market is anchored by a dedicated field sales force (Pharmaberater) maintaining direct in-person relationships with approximately 23,500 office-based physicians across Germany, supplemented by digital engagement tools ('Erfolgs-Rezept direkt', 'Erfolgs-Rezept online'), medical congress presence, and an English/German corporate website. Customer segments include primary-care physicians (primary), specialists, retail and hospital pharmacies, and pharmaceutical company partners seeking primary-care market access. Pricing follows standard ex-works Germany unit pricing with tiered minimum-order rules, free-house delivery above €150, a 5% small-order surcharge below €500, and 30-day net payment terms with 1% SEPA discount within 10 days. Distribution is contractually restricted to Germany — international sales are prohibited without explicit written consent.

Short descriptiontext

APONTIS PHARMA is a German specialty pharmaceutical company that develops, in-licenses, and markets Single Pill fixed-dose cardiovascular combinations via a field sales force reaching ~23,500 office-based physicians in Germany, operating within the Zentiva Group.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersMonheim am Rhein, Germany
HQ citystring
Monheim am Rhein
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiovascular pharmaceuticals, single pill combinations, fixed-dose combinations, hypertension treatment, pharmaceutical wholesale
Industry4 codes
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Cardiovascular Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

APONTIS PHARMA generates revenue through the sale of proprietary and licensed Single Pill products (fixed-dose combinations) and other pharmaceutical medications to the German healthcare market. Products are distributed via wholesale chains to pharmacies and directly to hospital pharmacies and clinics. Revenue is derived from product pricing to institutional buyers (wholesalers, pharmacies, clinics) in Germany.

2Co-promotion & Fee-for-Call
TypeProfessional Services
Description

APONTIS PHARMA earns revenue through co-promotion arrangements and fee-for-call services with other pharmaceutical companies. Under co-promotion, the company promotes partner products alongside its own portfolio using its established field sales force and access to ~23,500 German physicians. Fee-for-call arrangements involve providing pharmaceutical consultant services to partners for specific products or campaigns.

Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Marketing or Sales, Supply Chain, Operations, Technology or R&D
Pricing details3 tiers
1Wholesale / distributor pricing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Products are sold to pharmaceutical wholesalers (Großhandel) who must resell in unopened original packaging exclusively to pharmacies. Minimum order quantities are specified in APONTIS PHARMA price lists.

2Pharmacy pricing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Pharmacies and hospital Vollapotheken purchase products in unopened original packaging. Delivery free Haus (free delivery) applies for orders from clinics and hospital-supplying pharmacies above €150. Below that threshold, a postage and packaging fee of €8.00 is charged.

3Clinic / hospital pricing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

For clinic supply, delivery free Haus above €150 order value; otherwise €8.00 surcharge. Small orders below €500 incur a 5% minimum quantity surcharge. Orders above €2,000 carry no delivery surcharge. All pricing is ex-works Germany and excludes VAT.

GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

APONTIS PHARMA develops, in-licenses, and markets Single Pills — fixed-dose combinations of two to three off-patent active ingredients — primarily for cardiovascular diseases (hypertension, dyslipidemia, secondary prophylaxis). The portfolio includes eleven launched Single Pills marketed exclusively in Germany, supported by a dedicated field sales force of pharmaceutical consultants with access to approximately 23,500 office-based physicians. The company also engages in co-promotion, fee-for-call, and licensing arrangements with partner pharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Patient adherence increases from 20-50% (conventional) to 70-80% (Single Pill)
+4 more records
Product overview1 text field

APONTIS PHARMA is a pharmaceutical company known as 'The Single Pill Company', specializing in the development and marketing of Single Pills - combination products that merge two to three off-patent active ingredients in a single dosage form. The core portfolio consists of Single Pills for cardiovascular diseases (hypertension, dyslipidemia, cardiovascular secondary prophylaxis) and respiratory products. Single Pills include combinations such as Tonotec® (Ramipril/Amlodipine), Caramlo® (Candesartan/Amlodipine), AmloAtor® (Amlodipine/Atorvastatin), Iltria® (Triple: Aspirin/Atorvastatin/Ramipril), and numerous other cardiovascular combinations. The company also markets respiratory products (Atectura® Breezhaler®, Enerzair® Breezhaler®), Colxi® (Colchicine), and general healthcare products. As of 2026, the company aims to expand from 11 to at least 20 marketed Single Pills, targeting approximately 9 million potential patients.

Product and service15 records
1Tonotec®
CategorySingle Pill (Cardiovascular)
Description

Single Pill combining Ramipril and Amlodipine for cardiovascular treatment - first Single Pill launched in 2013.

2Caramlo®
CategorySingle Pill (Cardiovascular)
Description

Single Pill combining Candesartancilexetil and Amlodipine for hypertension.

3Biramlo®
CategorySingle Pill (Cardiovascular)
Description

Single Pill combining Bisoprololfumarat and Amlodipine for cardiovascular treatment.

4Atorimib® APONTIS®
CategorySingle Pill (Cardiovascular)
Description

Single Pill combining Ezetimib and Atorvastatin for lipid management.

5AmloAtor® APONTIS®
CategorySingle Pill (Cardiovascular)
Description

Single Pill combining Amlodipine and Atorvastatin for treatment of hypertension and dyslipidemia.

6Caramlo® Ator APONTIS®
CategorySingle Pill (Cardiovascular)
Description

Triple combination Single Pill with Candesartancilexetil, Amlodipine, and Atorvastatin for comprehensive cardiovascular care.

7ValsaInda® APONTIS®
CategorySingle Pill (Cardiovascular)
Description

Single Pill combining Valsartan and Indapamid for hypertension.

8CandeInda® APONTIS®
CategorySingle Pill (Cardiovascular)
Description

Single Pill combining Candesartancilexetil and Indapamid for hypertension.

9Atectura® Breezhaler®
CategoryRespiratory Product
Description

Indacaterol/Mometasonfuroat inhaler for asthma treatment.

10Enerzair® Breezhaler®
CategoryRespiratory Product
Description

Indacaterol/Glycopyrronium/Mometasonfuroat inhaler for asthma treatment.

11Colxi®
CategoryCore Product
Description

Colchicine product for anti-inflammatory treatment.

12Codicaps® mono
CategoryCore Product
Description

Codein Monohydrat product.

13magno sanol®
CategoryCore Product
Description

Magnesiumoxid supplement.

14magno sanol® uno
CategoryCore Product
Description

Magnesium supplement product.

15Obstinol® M
CategoryCore Product
Description

Viscous Paraffin product.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1AmloAtor Product Partner (name not disclosed in source)
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

AmloAtor (Amlodipin/Atorvastatin) was launched in 2022 as a Single Pill combination product for the treatment of hypertension and dyslipidemia. APONTIS PHARMA co-promotes this product on the German market with a partner company. AmloAtor represents one of the company's newer flagship Single Pill products addressing a common comorbidity in cardiovascular patients.

2Tonotec Product Partner (name not disclosed in source)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2013-01-01
Description

Tonotec (Ramipril/Amlodipin) was launched in 2013 as a Single Pill combination product. APONTIS PHARMA specializes in the development and in-licensing of fixed-dose combinations of off-patent active ingredients, and co-promotes the Tonotec brand on the German market with a partner company. The partnership has been sustained through the company's transitions from Schwarz Pharma to UCB Innere Medizin and then to APONTIS PHARMA.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

APONTIS PHARMA operates as part of the Zentiva Group, an international pharmaceutical company headquartered in Prague, Czech Republic. APONTIS PHARMA and Zentiva Group (together with further affiliated companies) act as joint controllers under GDPR (Art. 26 DSGVO) for data processing purposes. Zentiva also provides the Speak-Up whistleblowing platform for APONTIS's corporate governance framework. The Zentiva partnership provides strategic oversight, shared corporate services, and access to the broader Zentiva network.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Aristo Pharma is a German specialty generics company with cardiovascular and chronic disease products. Comparable as a Germany-focused pharma with cardiovascular offerings and a similar mid-market positioning.

TypeEmerging player
Description

Hexal is a leading German generics manufacturer with cardiovascular portfolio. Comparable as a Germany-based company with cardiovascular offerings targeting the same primary care physician channel, though focused on generics rather than branded FDCs.

TypeDirect peer
Description

Stada is a German specialty pharma with cardiovascular and chronic disease products, including FDC offerings. Comparable as a mid-size European specialty pharma with German market focus and field sales force model.

TypeDirect peer
Description

Berlin-Chemie is a major German pharmaceutical company with strong cardiovascular portfolio and primary care physician relationships. Comparable as a Germany-focused cardiovascular pharma with established field sales infrastructure.

TypeBroad incumbent
Description

Parent company of APONTIS PHARMA. Zentiva is a major European generics and specialty pharma company with broad cardiovascular and chronic disease portfolios. Comparable as the parent organization with overlapping cardiovascular FDC focus and shared distribution infrastructure.

TypeDirect peer
Description

Servier markets cardiovascular FDC products (e.g., Coversyl combinations, Viacoram) in Germany. Comparable as a cardiovascular-focused pharma with fixed-dose combination strategy targeting the same physician segments.

TypeDirect peer
Description

Daiichi Sankyo markets Sevikar (olmesartan/amlodipine) and other cardiovascular FDC products in Germany. Directly comparable as a cardiovascular fixed-dose combination competitor targeting the same German primary care physician base.

TypeBroad incumbent
Description

Bayer is a major German pharmaceutical company with a significant cardiovascular portfolio and established physician relationships. Comparable as a broad incumbent in the same cardiovascular therapeutic area with overlapping primary care reach.

TypeBroad incumbent
Description

Novartis markets Exforge (amlodipine/valsartan) and other cardiovascular FDC products in Germany. Comparable as a major incumbent with overlapping cardiovascular FDC portfolio and established German primary care presence.

TypeBroad incumbent
Description

AstraZeneca markets Caduet (amlodipine/atorvastatin) and other cardiovascular products in Germany. Comparable as a major incumbent with direct overlap in the amlodipine/atorvastatin FDC space that APONTIS addresses with AmloAtor®.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

APONTIS PHARMA

Cardiovascular Pharmaceuticalsapontis-pharma.de

APONTIS PHARMA is a German specialty pharmaceutical company that develops, in-licenses, and markets Single Pill fixed-dose cardiovascular combinations via a field sales force reaching ~23,500 office-based physicians in Germany, operating within the Zentiva Group.

What APONTIS PHARMA does

APONTIS PHARMA Deutschland GmbH & Co. KG is a Germany-focused specialty pharmaceutical company headquartered in Monheim am Rhein, operating as 'The Single Pill Company'. It develops, in-licenses, and markets fixed-dose combination products ('Single Pills') that merge two to three off-patent active ingredients into a single tablet, primarily for cardiovascular indications including hypertension, dyslipidemia, and cardiovascular secondary prophylaxis. The portfolio currently includes 11 launched Single Pill brands (e.g., Tonotec, Caramlo, AmloAtor APONTIS, Iltria, RosuAmlo APONTIS) with a stated goal of at least 20 by 2026, alongside co-promoted respiratory products (Atectura Breezhaler, Enerzair Breezhaler) and legacy brands such as Colxi, magno sanol, and Obstinol M. The company was founded in 1946 as Schwarz Pharma, became part of UCB's Internal Medicine segment, was carved out in 2016, acquired by Paragon Partners in 2018, renamed APONTIS PHARMA in 2019, and completed an IPO in May 2021; it now operates as part of the Zentiva Group (Prague-headquartered) under joint GDPR controllership.

The company makes money primarily through wholesale pharmaceutical product sales in Germany, distributed through the regulated German pharma supply chain (wholesalers → pharmacies → patients, plus direct clinic supply under §14 Apothekengesetz). A secondary revenue stream comes from co-promotion and fee-for-call arrangements where APONTIS PHARMA deploys its field sales force to promote partner products to its established physician base. Go-to-market is anchored by a dedicated field sales force (Pharmaberater) maintaining direct in-person relationships with approximately 23,500 office-based physicians across Germany, supplemented by digital engagement tools ('Erfolgs-Rezept direkt', 'Erfolgs-Rezept online'), medical congress presence, and an English/German corporate website. Customer segments include primary-care physicians (primary), specialists, retail and hospital pharmacies, and pharmaceutical company partners seeking primary-care market access. Pricing follows standard ex-works Germany unit pricing with tiered minimum-order rules, free-house delivery above €150, a 5% small-order surcharge below €500, and 30-day net payment terms with 1% SEPA discount within 10 days. Distribution is contractually restricted to Germany — international sales are prohibited without explicit written consent.

APONTIS PHARMA firmographics

Firmographics
Name
APONTIS PHARMA
Legal name
APONTIS PHARMA Deutschland GmbH & Co. KG
Website
https://apontis-pharma.de
Company type
Public
Founded year
1946
Operating status
Operating
Headcount range
101–250 employees
Short description
APONTIS PHARMA is a German specialty pharmaceutical company that develops, in-licenses, and markets Single Pill fixed-dose cardiovascular combinations via a field sales force reaching ~23,500 office-based physicians in Germany, operating within the Zentiva Group.
Ownership category
akta.pro rank

APONTIS PHARMA industry classification

Industry
Product category
Cardiovascular Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Cardiovascular pharmaceuticals
  • Single pill combinations
  • Fixed-dose combinations
  • Hypertension treatment
  • Pharmaceutical wholesale

Where APONTIS PHARMA is headquartered

Location

Headquarters

HQ city
Monheim am Rhein
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

APONTIS PHARMA business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Marketing or Sales, Supply Chain, Operations, Technology or R&D

Revenue model

  1. Pharmaceutical Product Sales: APONTIS PHARMA generates revenue through the sale of proprietary and licensed Single Pill products (fixed-dose combinations) and other pharmaceutical medications to the German healthcare market. Products are distributed via wholesale chains to pharmacies and directly to hospital pharmacies and clinics. Revenue is derived from product pricing to institutional buyers (wholesalers, pharmacies, clinics) in Germany.
  2. Co-promotion & Fee-for-Call: APONTIS PHARMA earns revenue through co-promotion arrangements and fee-for-call services with other pharmaceutical companies. Under co-promotion, the company promotes partner products alongside its own portfolio using its established field sales force and access to ~23,500 German physicians. Fee-for-call arrangements involve providing pharmaceutical consultant services to partners for specific products or campaigns.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goWholesale / distributor pricing
Unit PricingPay-as-you-goPharmacy pricing
Unit PricingPay-as-you-goClinic / hospital pricing

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

APONTIS PHARMA product offering

Product offering

Core offering

APONTIS PHARMA develops, in-licenses, and markets Single Pills — fixed-dose combinations of two to three off-patent active ingredients — primarily for cardiovascular diseases (hypertension, dyslipidemia, secondary prophylaxis). The portfolio includes eleven launched Single Pills marketed exclusively in Germany, supported by a dedicated field sales force of pharmaceutical consultants with access to approximately 23,500 office-based physicians. The company also engages in co-promotion, fee-for-call, and licensing arrangements with partner pharmaceutical companies.

Product overview

APONTIS PHARMA is a pharmaceutical company known as 'The Single Pill Company', specializing in the development and marketing of Single Pills - combination products that merge two to three off-patent active ingredients in a single dosage form. The core portfolio consists of Single Pills for cardiovascular diseases (hypertension, dyslipidemia, cardiovascular secondary prophylaxis) and respiratory products. Single Pills include combinations such as Tonotec® (Ramipril/Amlodipine), Caramlo® (Candesartan/Amlodipine), AmloAtor® (Amlodipine/Atorvastatin), Iltria® (Triple: Aspirin/Atorvastatin/Ramipril), and numerous other cardiovascular combinations. The company also markets respiratory products (Atectura® Breezhaler®, Enerzair® Breezhaler®), Colxi® (Colchicine), and general healthcare products. As of 2026, the company aims to expand from 11 to at least 20 marketed Single Pills, targeting approximately 9 million potential patients.

Differentiator

Problem solved

Functional benefit

Products and services

  • Tonotec® Single Pill combining Ramipril and Amlodipine for cardiovascular treatment - first Single Pill launched in 2013.
  • Caramlo® Single Pill combining Candesartancilexetil and Amlodipine for hypertension.
  • Biramlo® Single Pill combining Bisoprololfumarat and Amlodipine for cardiovascular treatment.
  • Atorimib® APONTIS® Single Pill combining Ezetimib and Atorvastatin for lipid management.
  • AmloAtor® APONTIS® Single Pill combining Amlodipine and Atorvastatin for treatment of hypertension and dyslipidemia.
  • Caramlo® Ator APONTIS® Triple combination Single Pill with Candesartancilexetil, Amlodipine, and Atorvastatin for comprehensive cardiovascular care.
  • ValsaInda® APONTIS® Single Pill combining Valsartan and Indapamid for hypertension.
  • CandeInda® APONTIS® Single Pill combining Candesartancilexetil and Indapamid for hypertension.
  • Atectura® Breezhaler® Indacaterol/Mometasonfuroat inhaler for asthma treatment.
  • Enerzair® Breezhaler® Indacaterol/Glycopyrronium/Mometasonfuroat inhaler for asthma treatment.
  • Colxi® Colchicine product for anti-inflammatory treatment.
  • Codicaps® mono Codein Monohydrat product.
  • magno sanol® Magnesiumoxid supplement.
  • magno sanol® uno Magnesium supplement product.
  • Obstinol® M Viscous Paraffin product.

Quantifiable outcome

  • Patient adherence increases from 20-50% (conventional) to 70-80% (Single Pill)
  • +4 more outcomes

Companies that use APONTIS PHARMA

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles3 records

APONTIS PHARMA technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

APONTIS PHARMA partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered flagship and core.

  • AmloAtor Product Partner (name not disclosed in source)flagshipStrategic or Co-development Partner · 1 January 2022AmloAtor (Amlodipin/Atorvastatin) was launched in 2022 as a Single Pill combination product for the treatment of hypertension and dyslipidemia. APONTIS PHARMA co-promotes this product on the German market with a partner company. AmloAtor represents one of the company's newer flagship Single Pill products addressing a common comorbidity in cardiovascular patients.
  • Tonotec Product Partner (name not disclosed in source)coreStrategic or Co-development Partner · 1 January 2013Tonotec (Ramipril/Amlodipin) was launched in 2013 as a Single Pill combination product. APONTIS PHARMA specializes in the development and in-licensing of fixed-dose combinations of off-patent active ingredients, and co-promotes the Tonotec brand on the German market with a partner company. The partnership has been sustained through the company's transitions from Schwarz Pharma to UCB Innere Medizin and then to APONTIS PHARMA.
  • Zentiva Group (Zentiva Group, a.s.)flagshipStrategic or Co-development PartnerAPONTIS PHARMA operates as part of the Zentiva Group, an international pharmaceutical company headquartered in Prague, Czech Republic. APONTIS PHARMA and Zentiva Group (together with further affiliated companies) act as joint controllers under GDPR (Art. 26 DSGVO) for data processing purposes. Zentiva also provides the Speak-Up whistleblowing platform for APONTIS's corporate governance framework. The Zentiva partnership provides strategic oversight, shared corporate services, and access to the broader Zentiva network.

Scale indicators9 records

Recent moves10 records

Expansion highlights5 records

APONTIS PHARMA competitors and assessment

Company assessment

Emerging players

  • Aristo Pharma: Aristo Pharma is a German specialty generics company with cardiovascular and chronic disease products. Comparable as a Germany-focused pharma with cardiovascular offerings and a similar mid-market positioning.
  • Hexal (Sandoz): Hexal is a leading German generics manufacturer with cardiovascular portfolio. Comparable as a Germany-based company with cardiovascular offerings targeting the same primary care physician channel, though focused on generics rather than branded FDCs.

Direct peers

  • Stada Arzneimittel: Stada is a German specialty pharma with cardiovascular and chronic disease products, including FDC offerings. Comparable as a mid-size European specialty pharma with German market focus and field sales force model.
  • Berlin-Chemie (Menarini Group): Berlin-Chemie is a major German pharmaceutical company with strong cardiovascular portfolio and primary care physician relationships. Comparable as a Germany-focused cardiovascular pharma with established field sales infrastructure.
  • Servier Deutschland: Servier markets cardiovascular FDC products (e.g., Coversyl combinations, Viacoram) in Germany. Comparable as a cardiovascular-focused pharma with fixed-dose combination strategy targeting the same physician segments.
  • Daiichi Sankyo Deutschland: Daiichi Sankyo markets Sevikar (olmesartan/amlodipine) and other cardiovascular FDC products in Germany. Directly comparable as a cardiovascular fixed-dose combination competitor targeting the same German primary care physician base.

Broad incumbents

  • Zentiva Group: Parent company of APONTIS PHARMA. Zentiva is a major European generics and specialty pharma company with broad cardiovascular and chronic disease portfolios. Comparable as the parent organization with overlapping cardiovascular FDC focus and shared distribution infrastructure.
  • Bayer Vital (Bayer Pharma): Bayer is a major German pharmaceutical company with a significant cardiovascular portfolio and established physician relationships. Comparable as a broad incumbent in the same cardiovascular therapeutic area with overlapping primary care reach.
  • Novartis Pharma Germany: Novartis markets Exforge (amlodipine/valsartan) and other cardiovascular FDC products in Germany. Comparable as a major incumbent with overlapping cardiovascular FDC portfolio and established German primary care presence.
  • AstraZeneca Germany: AstraZeneca markets Caduet (amlodipine/atorvastatin) and other cardiovascular products in Germany. Comparable as a major incumbent with direct overlap in the amlodipine/atorvastatin FDC space that APONTIS addresses with AmloAtor®.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

APONTIS PHARMA social profiles

Digital presence

APONTIS PHARMA compliance and trust

Trust signal

Compliance3 records

APONTIS PHARMA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

APONTIS PHARMA leadership team

Management profile

Number of profiles

Profiles11 records

APONTIS PHARMA funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

APONTIS PHARMA M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about APONTIS PHARMA

What does APONTIS PHARMA do?

APONTIS PHARMA develops, in-licenses, and markets Single Pills — fixed-dose combinations of two to three off-patent active ingredients — primarily for cardiovascular diseases (hypertension, dyslipidemia, secondary prophylaxis). The portfolio includes eleven launched Single Pills marketed exclusively in Germany, supported by a dedicated field sales force of pharmaceutical consultants with access to approximately 23,500 office-based physicians. The company also engages in co-promotion, fee-for-call, and licensing arrangements with partner pharmaceutical companies.

Is APONTIS PHARMA a public or private company?

APONTIS PHARMA is a public company. It is classified as public and is currently operating.

When was APONTIS PHARMA founded?

APONTIS PHARMA was founded in 1946. It employs 101 to 250 people.

Where is APONTIS PHARMA based?

APONTIS PHARMA is headquartered in Monheim am Rhein, Germany, in the Europe region.

How does APONTIS PHARMA make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are co-promotion & Fee-for-Call.

Who are APONTIS PHARMA's main competitors?

Emerging players on record are Aristo Pharma and Hexal (Sandoz). Direct peers are Stada Arzneimittel, Berlin-Chemie (Menarini Group), Servier Deutschland and Daiichi Sankyo Deutschland. Broad incumbents are Zentiva Group, Bayer Vital (Bayer Pharma), Novartis Pharma Germany and AstraZeneca Germany.

Does APONTIS PHARMA have an API?

No public API is recorded for APONTIS PHARMA.

What industry is APONTIS PHARMA in?

APONTIS PHARMA's product category is Cardiovascular Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireZentiva obtient environ 85,27 % des droits de vote d'APONTIS PHARMA AG dans le cadre de son offre publique d'achatZentiva AG, a wholly-owned subsidiary of Zentiva Pharma GmbH, said on November 27, 2024 that it acquired roughly 83.57% of APONTIS PHARMA AG's share capital and about 85.27% of voting rights through its voluntary public bid, closing on November 21, 2024. The deal's settlement awaits German foreign investment control approval, expected in December 2024 or the first quarter of 2025.PR NewswireZentiva sichert sich ca. 85,27 % der Stimmrechte der APONTIS PHARMA AG im Rahmen ihres öffentlichen KaufangebotsZentiva AG, a subsidiary of Zentiva Pharma GmbH, has secured approximately 83.57% of share capital and 85.27% of voting rights in APONTIS PHARMA AG following the expiration of the acceptance period on November 21, 2024. The settlement remains subject to approval from the German foreign investment supervisory authority and is expected to be completed in December 2024 or the first quarter of 2025. The acquisition marks a significant step in Zentiva's strategy to expand its reach and strengthen its portfolio of affordable pharmaceutical products across Europe.PR NewswireZentiva secures approx. 85.27% of APONTIS PHARMA AG voting rights in the context of its public purchase offerZentiva AG, a German pharmaceutical company, has secured approximately 83.57% of share capital and 85.27% of voting rights in APONTIS PHARMA AG following the end of its voluntary public purchase offer's acceptance period on November 21, 2024. The transaction marks a significant step in Zentiva's strategy to expand its European presence and pharmaceutical portfolio. Settlement remains contingent on foreign direct investment control clearance in Germany, with completion expected in December 2024 or Q1 2025.PR NewswireZentiva se hace con aproximadamente el 85,27% de los derechos de voto de APONTIS PHARMA AGZentiva AG, a Frankfurt-based pharmaceutical company and subsidiary of Zentiva Pharma GmbH, has secured approximately 83.57% of the share capital and 85.27% of the voting rights of APONTIS PHARMA AG following the close of its voluntary public takeover offer on 21 November 2024. The transaction is pending German foreign direct investment control approval, with settlement expected in December 2024 or the first quarter of 2025. CEO Steffen Saltofte stated that the acquisition represents a major step in expanding Zentiva's reach and strengthening its capacity to supply affordable, high-quality medicines across Europe.PR NewswireZentiva secures approx. 85.27% of APONTIS PHARMA AG voting rights in the context of its public purchase offerZentiva AG, a subsidiary of Zentiva Pharma GmbH headquartered in Frankfurt, Germany, has secured approximately 83.57% of share capital and 85.27% of voting rights in APONTIS PHARMA AG following the end of the acceptance period on 21 November 2024. The voluntary public purchase offer represents a significant step in Zentiva's expansion strategy across Europe. Settlement of the offer remains subject to foreign direct investment control clearance in Germany and is expected to occur in December 2024 or Q1 2025.PharmiWeb.comAPONTIS PHARMA and Zentiva enter into investment agreement – Zentiva will launch a voluntary public purchase offerZentiva signed an investment agreement with APONTIS PHARMA to launch a voluntary public purchase offer for all outstanding shares at EUR 10.00 per share. The offer requires a 65% acceptance threshold and Zentiva holds about 37.5% of shares. APONTIS PHARMA will apply to cancel OTC trading inclusion.Business InsiderEQS-News: APONTIS PHARMA and Zentiva entered into partnership for future growth – Zentiva will launch a voluntary public purchase offerZentiva signed an investment agreement with APONTIS PHARMA and will launch a voluntary public purchase offer at EUR 10.00 per share, a 52.9% premium over the last trading day's closing price. The offer sets a minimum acceptance threshold of 65% and Zentiva has already secured about 37.5% of the shares.UnquoteParagon's Apontis Pharma completes IPOApontis Pharma, a Paragon Partners portfolio company, listed on the Frankfurt Stock Exchange on 7 May 2021 at €18.90 per share. The IPO raised €101m, giving a market capitalization of €162m, with Paragon retaining a 31% stake. Proceeds will support ongoing product development.